Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

By afschroeder • June 30, 2026

Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Çiçin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard D, Lee SH, Mansfield AS, Moskovitz M, Baijal S, Baik C, Hrom JS, Heist RS, Yazici O, Verma M, Uema D, Patel S, Xia S, Ratajczak C, Camidge DR. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. JTO Clin Res Rep. 2026 Mar 16;7(7):100988. doi: 10.1016/j.jtocrr.2026.100988. PMID: 42368479; PMCID: PMC13293683.

Tags: Antibody–drug conjugate, Biomarker, c-Met protein, Hematology/Oncology, NSCLC, Publications, Telisotuzumab vedotin

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review

Smith CE, Sammons SL, Minami CA, Sedrak MS, Magnuson A, O'Connor T, Hshieh TT, Smith S, Ruderman K, Bak K, Lin NU, Freedman RA. Systemic[...]

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers

Shachar EK, Silverstein J, Gornbein J, Salani R, Karlan BY, Chase DM. Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related[...]

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano[...]